Fairmount Funds Management as of Dec. 31, 2024
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 17 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Axsome Therapeutics (AXSM) | 12.4 | $124M | 1.5M | 84.61 | |
| Nuvalent Inc-a (NUVL) | 10.3 | $103M | 1.3M | 78.28 | |
| Spyre Therapeutics Com New (SYRE) | 9.3 | $94M | 4.0M | 23.28 | |
| Apogee Therapeutics (APGE) | 9.2 | $93M | 2.0M | 45.30 | |
| Scholar Rock Hldg Corp (SRRK) | 8.4 | $85M | 2.0M | 43.22 | |
| Enliven Therapeutics (ELVN) | 7.2 | $72M | 3.2M | 22.50 | |
| Miragen Therapeutics (VRDN) | 6.6 | $66M | 3.4M | 19.17 | |
| Oruka Therapeutics (ORKA) | 6.5 | $65M | 3.4M | 19.39 | |
| Dianthus Therapeutics (DNTH) | 5.9 | $59M | 2.7M | 21.80 | |
| Cogent Biosciences (COGT) | 4.8 | $49M | 6.2M | 7.80 | |
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 4.3 | $43M | 2.2M | 19.78 | |
| Day One Biopharmaceuticals I (DAWN) | 3.9 | $39M | 3.1M | 12.67 | |
| Astria Therapeutics (ATXS) | 3.2 | $32M | 3.6M | 8.94 | |
| Anaptysbio Inc Common (ANAB) | 2.4 | $24M | 1.8M | 13.24 | |
| Bicara Therapeutics (BCAX) | 2.2 | $22M | 1.3M | 17.42 | |
| Inhibikase Therapeutics Com New (IKT) | 2.0 | $20M | 6.1M | 3.25 | |
| Zenas Biopharma (ZBIO) | 1.5 | $16M | 1.9M | 8.19 |
